id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16577 R69636 |
Battino (Epilepsy), 2024 | Major congenital malformations (MCMs) | early pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.75 [0.23;13.26] C | 1/19 110/3,584 | 111 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12866 R48560 |
Thomas (Epilepsy) (Controls exposed to Lamotrigine, sick), 2021 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
13.36 [1.27;140.94] C excluded (control group) |
3/14 1/50 | 4 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12867 R48570 |
Thomas (Epilepsy) (Controls unexposed, sick), 2021 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 5.52 [1.40;21.77] C | 3/14 16/340 | 19 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7790 R35201 |
Vajda (Epilepsy) (Controls exposed to Lamotrigine, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
6.27 [0.25;158.67] C excluded (control group) |
0/2 20/406 | 20 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7791 R35202 |
Vajda (Epilepsy) (Controls unexposed, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 10.33 [0.38;283.37] C | 0/2 5/176 | 5 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6649 R26912 |
Kini (Epilepsy) (Controls exposed to Lamotrigine, sick), 2007 | Major malformations | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
29.00 [0.23;3625.72] C excluded (control group) |
0/1 0/15 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6639 R26913 |
Kini (Epilepsy) (Controls unexposed, disease free), 2007 | Major malformations | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
41.91 [0.76;2311.57] C excluded (control group) |
0/1 5/236 | 5 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6644 R26914 |
Kini (Epilepsy) (Controls unexposed, sick), 2007 | Major malformations | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
67.00 [0.54;8247.13] C excluded (exposition period) |
0/1 0/34 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8390 R26910 |
Hvas (Epilepsy) (Controls unexposed, disease free), 2000 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
83.94 [1.66;4238.34] C excluded (control group) |
0/1 280/23,827 | 280 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8391 R26911 |
Hvas (Epilepsy) (Controls unexposed, sick), 2000 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 211.00 [1.73;25761.82] C | 0/1 0/106 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 5.36 [1.56;18.43] | 135 | 36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Epilepsy; 2: Epilepsy) (Controls unexposed, sick; 3: Epilepsy) (Controls unexposed, sick; 4: Epilepsy) (Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 8390, 6649, 6639, 7790, 12866